65,437 trials
Chronic GVHD
Primary: Fraction of Participants With an Overall Response Rate (Complete Response [CR] + Partial Response [PR]) Reported With an 80% Confidence Interval at 6 Months — 0; 0.1667…
Advanced Solid Tumors
Primary: Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Adolescent Idiopathic Scoliosis
Primary: Overall Recruitment Rate — 1; 1 Participants
Meibomian Gland Dysfunction · Dry Eye Syndromes · Dry Eye
Primary: Changes in Tear Break Up Times (TBUT) to the 4-weeks Follow-up Exam — 4.3; 4.6; 3.0; 2.7 seconds
Cannabis Use
Primary: Average Craving Level - Active vs. Control Messages — 4.736; 4.629 score on a scale
Soft Tissue Injury
Primary: Tenderness (Algometry) Over the Initial 72 Hours — 1213.88; 1041.04; 850.79 Nxh/cm^2 — p=0.0221
COVID
Primary: Cohort 1, Phase 2: Percentage of Participants Alive and Free of Mechanical Ventilation at Day 29 — 85.7; 87.5; 74.4 percentage of participants — p=0.2598
COVID-19
Primary: COVID-19 Disease Incidence Rate (Symptomatic Infections Per Month) — 364.5 infections per 1000 person-years
Glaucoma, Open-Angle
Primary: Primary Safety Endpoint — 0; 0 adverse event
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Esophageal Adenocarcinoma
Primary: Number of Participants With Dose-limiting Toxicities (DLT) During the First Cycle of Treatment — 0; 2 Participants
Multiple Sclerosis
Primary: Percentage of Participants With No Evidence of Disease Activity (Three Parameter [NEDA-3]) During Year 3 to 4 — 54.23 percentage of participants
Intubation
Primary: Time to Intubate — 52.1; 42.0 seconds
Meningococcal Infections
Primary: Groups 1 and 2: Geometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, W, and Y — 131; 189; 565; 120 Titer
Airway Inflammation · Asthma
Primary: Fractional Exhaled Nitric Oxide (FeNO) — 8.67; 9.01 parts per billion (ppb)
Hemorrhage · Bleeding Hemorrhage
Primary: Number of Participants With Clinical Success: Cessation of Bleeding up to 24 Hours — 100 Participants